CL2007003730A1 - Nanoemulsion que comprende a) componente acuoso y b) un vehiculo con i) 0,1-15% de un componente lipofilico, ii) un tensoactivo y iii) un alcohol c3-c5; composicion que la comprende opcionalmente con un agente activo; proceso de preparacion de la nanoemulsion y de la composicion; kit; y uso para diagnosticar enfermedades dermicas y proliferativas, y tratar enfermedades virales, dermicas y proliferativas. - Google Patents

Nanoemulsion que comprende a) componente acuoso y b) un vehiculo con i) 0,1-15% de un componente lipofilico, ii) un tensoactivo y iii) un alcohol c3-c5; composicion que la comprende opcionalmente con un agente activo; proceso de preparacion de la nanoemulsion y de la composicion; kit; y uso para diagnosticar enfermedades dermicas y proliferativas, y tratar enfermedades virales, dermicas y proliferativas.

Info

Publication number
CL2007003730A1
CL2007003730A1 CL2007003730A CL2007003730A CL2007003730A1 CL 2007003730 A1 CL2007003730 A1 CL 2007003730A1 CL 2007003730 A CL2007003730 A CL 2007003730A CL 2007003730 A CL2007003730 A CL 2007003730A CL 2007003730 A1 CL2007003730 A1 CL 2007003730A1
Authority
CL
Chile
Prior art keywords
nanoemulsion
dermal
proliferative diseases
composition
alcohol
Prior art date
Application number
CL2007003730A
Other languages
English (en)
Inventor
Roca Montserrat Foguet
Original Assignee
Biofrontera Bioscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38042639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007003730(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biofrontera Bioscience Gmbh filed Critical Biofrontera Bioscience Gmbh
Publication of CL2007003730A1 publication Critical patent/CL2007003730A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm

Abstract

NANOEMULSION QUE COMPRENDE A) POR LO MENOS UN COMPONENTE ACUOSO Y B) UN VEHÍCULO QUE COMPRENDE, I) POR LO MENOS UN COMPONENTE LIPOFÍLICO, ESTANDO PRESENTE EN UNA CANTIDAD DE 0,1%-15% EN PESO II) POR LO MENOS UN TENSIOACTIVO Y III) POR LO MENOS UN ALCOHOL, DONDE EL POR LO MENOS UN ALCOHOL TIENE ENTRE TRES Y CINCO ÁTOMOS DE CARBONO Y DONDE EL DIAMETRO PROMEDIO  DE LAS PARTICULAS EMULSIFICADAS ES MENOR A 100 NM; COMPOSICIÓN FARMACÉUTICA  Y/O COSMÉTICA QUE COMPRENDE DICHA NANOEMULSION PROCEDIMIENTO PARA LA PREPARACIÓN DE DICHA NANOEMULSIÓN Y COMPOSICIÓN; KIT; USO PARA DIAGNOSTICAR ENFERMEDADES DÉRMICAS Y PROLIFERATIVAS: Y USO PARA TRATAR ENFERMEDADES VIRALES, DÉRMICAS Y PROLIFERATIVAS.
CL2007003730A 2006-12-22 2007-12-20 Nanoemulsion que comprende a) componente acuoso y b) un vehiculo con i) 0,1-15% de un componente lipofilico, ii) un tensoactivo y iii) un alcohol c3-c5; composicion que la comprende opcionalmente con un agente activo; proceso de preparacion de la nanoemulsion y de la composicion; kit; y uso para diagnosticar enfermedades dermicas y proliferativas, y tratar enfermedades virales, dermicas y proliferativas. CL2007003730A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06026698A EP1938801A1 (en) 2006-12-22 2006-12-22 Nanoemulsion

Publications (1)

Publication Number Publication Date
CL2007003730A1 true CL2007003730A1 (es) 2009-01-23

Family

ID=38042639

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007003730A CL2007003730A1 (es) 2006-12-22 2007-12-20 Nanoemulsion que comprende a) componente acuoso y b) un vehiculo con i) 0,1-15% de un componente lipofilico, ii) un tensoactivo y iii) un alcohol c3-c5; composicion que la comprende opcionalmente con un agente activo; proceso de preparacion de la nanoemulsion y de la composicion; kit; y uso para diagnosticar enfermedades dermicas y proliferativas, y tratar enfermedades virales, dermicas y proliferativas.

Country Status (18)

Country Link
US (2) US11540981B2 (es)
EP (2) EP1938801A1 (es)
JP (1) JP5558827B2 (es)
CN (1) CN101588792B (es)
AR (1) AR064659A1 (es)
AU (1) AU2007338323B2 (es)
BR (1) BRPI0720853A2 (es)
CA (1) CA2670715C (es)
CL (1) CL2007003730A1 (es)
ES (1) ES2602107T3 (es)
IL (1) IL198934A (es)
MX (1) MX2009006088A (es)
NZ (1) NZ577061A (es)
RU (1) RU2491917C2 (es)
UA (1) UA101471C2 (es)
UY (1) UY30833A1 (es)
WO (1) WO2008077641A1 (es)
ZA (1) ZA200903468B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
SG177184A1 (en) 2006-12-01 2012-01-30 Anterios Inc Amphiphilic entity nanoparticles
EP2091516A2 (en) 2006-12-01 2009-08-26 Anterios, Inc. Peptide nanoparticles and uses therefor
KR20100050443A (ko) 2007-05-31 2010-05-13 안테리오스, 인코퍼레이티드 핵산 나노입자 및 이의 용도
JP2010143848A (ja) * 2008-12-18 2010-07-01 Kao Corp 化粧料
CN101874795A (zh) * 2009-04-28 2010-11-03 上海复旦张江生物医药股份有限公司 5-氨基酮戊酸在制备治疗hpv病毒感染的药物的用途
AU2010283998B2 (en) * 2009-08-21 2015-01-29 Targeted Delivery Technologies Limited Vesicular formulations
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
WO2011103510A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha ester emulsions
DE202010004750U1 (de) 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut
KR20130028967A (ko) * 2010-06-23 2013-03-20 브라잇사이드 이노베이션스 인크. 레시틴 캐리어 베시클 및 이의 제조 방법
BRPI1002486B1 (pt) 2010-07-22 2017-07-18 Evidence Soluções Farmacêuticas Ltda Epp Stabilized topical composition and process of obtaining composition stable topic
JP2012051823A (ja) * 2010-08-31 2012-03-15 Fujifilm Corp 難容性薬物含有水中油型乳化組成物及びその製造方法
JP5522421B2 (ja) 2010-09-14 2014-06-18 学校法人東京農業大学 がん温熱療法の作用増強剤
US8992994B2 (en) 2010-10-21 2015-03-31 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis
US9789123B2 (en) 2010-10-21 2017-10-17 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
JP6030565B2 (ja) 2010-12-10 2016-11-24 エヌエス テクノロジーズ プロプライエタリー リミテッドＮｓ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｐｔｙ Ｌｔｄ ミニエマルション、同ミニエマルションを形成するための方法および医薬品の製造における同ミニエマルションの使用
EP2657346B1 (en) 2010-12-24 2017-08-23 ARKRAY, Inc. Method for detecting cancer cell
DE102010056192A1 (de) 2010-12-28 2012-06-28 Gabriele Blume Kolloidales Trägersystem mit penetrierenden Eigenschaften zum Einschließen lipophiler Wirkstoffe und Öle für die topische Anwendung
CN106924216A (zh) * 2011-01-24 2017-07-07 安特里奥公司 纳米颗粒组合物、其制剂和它们的用途
FR2977801B1 (fr) * 2011-07-11 2013-08-16 Fabre Pierre Dermo Cosmetique Dispositif et procede pour la sterilisation a ultra-haute temperature d'une emulsion, notamment dermo-cosmetique, instable a la temperature de sterilisation
CN102600178A (zh) * 2012-03-08 2012-07-25 西北农林科技大学 一种复方盐酸布替萘芬纳米乳及其制备方法
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
IN2014MN02213A (es) 2012-05-10 2015-07-10 Painreform Ltd
GB201208409D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
JP6112498B2 (ja) * 2012-07-20 2017-04-12 株式会社 Ｍ Ｌａｂｓ 防腐剤・界面活性剤フリーの化粧品原料液、化粧品及び化粧品原料液の調製法
US10137085B2 (en) 2014-03-19 2018-11-27 Nano And Advanced Materials Institute Limited Nanoemulsion for transdermal delivery and method of making the same
WO2015155703A2 (en) 2014-04-09 2015-10-15 Nanoceutica Laboratories Pvt. Ltd Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base
WO2016128858A1 (en) * 2015-02-11 2016-08-18 Towhidi Armin Extender for cryopreservation of bovine sperm
WO2016182926A1 (en) * 2015-05-08 2016-11-17 Affinsci Inc. Preparation of nanoemulsions
CN114042041B (zh) * 2015-05-21 2023-08-22 德玛万科学有限责任公司 局部药物组合物
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
DK3316856T3 (da) 2015-06-30 2021-06-28 Sequessome Tech Holdings Limited Blandede formuleringer
US10603508B2 (en) 2015-10-15 2020-03-31 Dusa Pharmaceuticals, Inc. Adjustable illuminators and methods for photodynamic therapy and diagnosis
EP3362145B1 (en) 2015-10-15 2021-01-06 DUSA Pharmaceuticals, Inc. Adjustable illuminator for photodynamic therapy and diagnosis
GB201522398D0 (en) * 2015-12-18 2016-02-03 Photocure As Device for photodynamic therapy
CN105997875B (zh) * 2016-07-19 2019-05-21 重庆医科大学 一种明显提高难溶性药物生物利用度的油包水型纳米乳及其制备方法
GB2546128A (en) * 2016-09-28 2017-07-12 Photocure Asa Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same
CA3044219A1 (en) 2016-11-21 2018-05-24 Eirion Therapeutics, Inc. Transdermal delivery of large agents
WO2019018408A1 (en) * 2017-07-17 2019-01-24 Andrea Willey METHOD OF PHOTODYNAMIC THERAPY AGAINST SKIN DISORDERS
CN107233303A (zh) * 2017-08-07 2017-10-10 苏州纳美特生物科技有限公司 一种氨基酮戊酸冷霜及其制备方法和应用
TWI719263B (zh) * 2017-10-27 2021-02-21 財團法人國家衛生研究院 用於鼻黏膜之奈米級乳液免疫載劑及其製備方法
US10959975B1 (en) * 2017-11-02 2021-03-30 The Tetra Corporation Antifungal composition, method of making composition, and method of using composition
US10357567B1 (en) * 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy
US20190358160A1 (en) * 2018-05-11 2019-11-28 Formulytica Pty Ltd Sub-micron emulsions
EP3583954A1 (en) * 2018-06-19 2019-12-25 neubourg skin care GmbH Nanodispersions of birch bark extract, electrospun fibers containing such nanodispersions and their use for the treatment of wounds
CN112584864A (zh) * 2018-08-23 2021-03-30 生物前沿生物科学有限公司 包括两种不同波长的曝光的光动力疗法
US11497229B2 (en) * 2018-08-31 2022-11-15 Kemin Industries, Inc. Technology for water dispersible phospholipids and lysophospholipids
CN113260257B (zh) * 2018-12-28 2022-09-06 南京善思生物科技有限公司 纳米农药制剂及其制备方法
CN110169990A (zh) * 2019-06-19 2019-08-27 苏普丘昆基蒂 牛至油治疗猪腹泻自乳化配方产品及制造工艺
CN114081851A (zh) * 2021-11-01 2022-02-25 苏州纳美特生物科技有限公司 保湿喷雾

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
TR27650A (tr) * 1993-04-14 1995-06-14 Colgate Palmolive Co Bir glikol mono-alkil eteri iceren mikroemülsiyon temizleme bilesimi.
CA2158724A1 (en) 1994-09-20 1996-03-21 Jue-Chen Liu Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid
US5780010A (en) 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
SE9503143D0 (sv) * 1995-09-12 1995-09-12 Astra Ab New preparation
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US5895786A (en) 1996-05-08 1999-04-20 New York Blood Center, Inc. Method for treating viral infections
ES2187612T3 (es) * 1996-09-16 2003-06-16 Nestle Sa Microemulsion comestible para recubrir productos alimenticios y su uso para tostar y convertirlos en crujientes en un microondas.
ATE190469T1 (de) * 1996-11-13 2000-04-15 Procter & Gamble Mikroemulsionsförmige desinfektionszusammensetzung
TWI241915B (en) * 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
US6620437B2 (en) * 1998-07-30 2003-09-16 Colgate-Palmolive Co. Water-in-oil microemulsion for providing cosmetic attributes to fabric softening base composition
DE19852245A1 (de) * 1998-11-12 2000-05-18 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Nanoemulsion
FR2787728B1 (fr) * 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2787703B1 (fr) * 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788449B1 (fr) * 1999-01-14 2001-02-16 Oreal Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2795960B1 (fr) * 1999-07-05 2001-10-19 Sanofi Elf Microemulsions stables pour l'administration d'acides gras a l'homme ou a l'animal, et utilisation de ces microemulsions
US7919113B2 (en) * 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
DE10003620A1 (de) * 2000-01-28 2001-08-02 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln
US20020155084A1 (en) * 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
US6823387B1 (en) * 2000-06-23 2004-11-23 Microsoft Corporation System and method for enhancing a server's ability to withstand a “SYN flood” denial of service attack
EP2269645A3 (en) * 2000-08-16 2011-01-12 The General Hospital Corporation doing business as Massachusetts General Hospital Topical aminolevulinic acid-photodynamic therapy for acne vulgaris
JP2002302414A (ja) 2000-12-26 2002-10-18 Kokuriyuudou:Kk スフィンゴ脂質構造物質含有乳化組成物及びその製造方法
US7314624B2 (en) * 2001-06-05 2008-01-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
US20030167033A1 (en) * 2002-01-23 2003-09-04 James Chen Systems and methods for photodynamic therapy
WO2004037225A2 (en) * 2002-10-25 2004-05-06 Foamix Ltd. Cosmetic and pharmaceutical foam
CA2522985A1 (en) * 2003-04-17 2004-10-28 Affectis Pharmaceuticals Ag Means and methods for diagnosing and treating affective disorders
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
WO2005027872A2 (en) 2003-06-04 2005-03-31 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
EP1598060A1 (en) 2004-05-18 2005-11-23 Nestec S.A. Oil-in-water emulsion for delivery
TWI365075B (en) * 2004-09-22 2012-06-01 Kao Corp Microemulsion
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
JP4444149B2 (ja) 2005-03-30 2010-03-31 株式会社ナリス化粧品 超微細エマルジョンで構成される皮膚外用剤
US20090130227A1 (en) * 2005-04-28 2009-05-21 Yoshiyasu Ito External preparation for skin

Also Published As

Publication number Publication date
NZ577061A (en) 2012-01-12
BRPI0720853A2 (pt) 2014-03-25
RU2009128179A (ru) 2011-01-27
EP2120872A1 (en) 2009-11-25
CN101588792A (zh) 2009-11-25
MX2009006088A (es) 2009-08-28
CA2670715A1 (en) 2008-07-03
IL198934A0 (en) 2010-02-17
JP2010513363A (ja) 2010-04-30
UY30833A1 (es) 2008-07-31
US20230201087A1 (en) 2023-06-29
EP1938801A1 (en) 2008-07-02
WO2008077641A1 (en) 2008-07-03
UA101471C2 (en) 2013-04-10
US20090324727A1 (en) 2009-12-31
EP2120872B1 (en) 2016-09-21
ES2602107T3 (es) 2017-02-17
US11540981B2 (en) 2023-01-03
AU2007338323B2 (en) 2013-07-11
AU2007338323A1 (en) 2008-07-03
CA2670715C (en) 2015-11-24
RU2491917C2 (ru) 2013-09-10
AR064659A1 (es) 2009-04-15
ZA200903468B (en) 2010-02-24
IL198934A (en) 2016-04-21
CN101588792B (zh) 2012-03-21
JP5558827B2 (ja) 2014-07-23

Similar Documents

Publication Publication Date Title
CL2007003730A1 (es) Nanoemulsion que comprende a) componente acuoso y b) un vehiculo con i) 0,1-15% de un componente lipofilico, ii) un tensoactivo y iii) un alcohol c3-c5; composicion que la comprende opcionalmente con un agente activo; proceso de preparacion de la nanoemulsion y de la composicion; kit; y uso para diagnosticar enfermedades dermicas y proliferativas, y tratar enfermedades virales, dermicas y proliferativas.
AR067364A1 (es) Formulaciones solidas de artropodicidas de carboxamida
ES2478820T3 (es) Tratamiento de degeneración macular
AR065887A1 (es) Producto para el cuidado oral y metodos de uso y fabricacion de los mismos
CL2013003621A1 (es) Composición farmacéutica inhalable que comprende una dispersión de partículas liposomales que contienen un agente bioactivo hidrófobo, tal como coq10, un fosfolípido, y un vehículo de dispersión acuosa, apta para aerosolización continua; método de preparación; método de administración; uso para tratar enfermedades del pulmón.
AR052033A1 (es) Composicion farmaceutica que comprende inhibidor de topoisomerasa i
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
AR075355A1 (es) Particula de suministro que contiene agentes beneficos
BR112016018673A2 (pt) Composições de sistemas de distribuição de nanoemulsão
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
ECSP088903A (es) Composiciones farmacéuticas de anticuerpo antagonista anti-cd40
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
AR049063A1 (es) Composiciones farmaceuticas inyectables de posaconazol con particulas estabilizadas
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
BR112014028069A2 (pt) composição farmacêutica oftálmica, processo para a preparação de uma composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, e, método para a prevenção ou tratamento de uma infecção fúngica
CL2011002217A1 (es) Suspension acuosa oral que comprende riluzol, un tensioactivo seleccionado de tensioactivos anionicos, tensioactivos no ionicos o una mezcla de ellos, y un agente de suspension seleccionado de arcillas esmectitas, celulosa microcristalina, gomas naturales o sus mezclas; y su uso para tratar esclerosis amiotrofica lateral.
AR072359A1 (es) Encapsulacion de agentes biologicamente activos
BR0307278A (pt) Formulação oral de liberação imediata, e, método para preparar uma formulação
ES2895910T3 (es) Composiciones multifásicas
AR041826A1 (es) Formulaciones de liberacion prolongada en formas de suspension
BRPI0418070A (pt) composição para cuidados pessoais, uso de uma uréia substituìda e método para reduzir a degradação da cor de uma composição para cuidados pessoais
BR112018016604A2 (pt) composição repelente de uso tópico compreendendo um ativo repelente contido em um sistema de micelas poliméricas nanométricas de liberação prolongada
CL2009000986A1 (es) Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina